Clinical trials: Kidney Donor
Ischemia-reperfusion Injury, Kidney Transplant; Complications
FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation
A first-in-human single center, randomized, double-blind, placebo-controlled trial, with primary objective to evaluate safety and tolerability of ex-vivo kidney allograft treatment with TUM012 to reduce ischemia-reperfusion…
- Trial name
- NCT05246618
- Testing
- TUM012
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- iCoat Medical AB
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Kidney Failure
Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion
An open-label study to assess the safety, efficacy, and tolerance of FCRx cell therapy in adult recipients within 12 months after kidney transplantation from a living donor.
- Trial name
- NCT00497926
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Talaris Therapeutics Inc.
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of Human Leukocyte Antigen (HLA)-Mismatched, Living Donor Kidney Transplants
The Phase 2 primary objective is to evaluate achievement of persistent mixed chimerism and withdrawal of at least one immunosuppression drug for a minimum of 6 months with no episodes of biopsy-proven acute rejection or…
- Trial name
- NCT03605654
- Testing
- MDR-102, Immunosuppressive Agents
- Sponsor
- Medeor Therapeutics, Inc.
Renal Transplantation
Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice.
- Trial name
- NCT00697112
- Testing
- Sirolimus
- Where
- 8 sites in Argentina
- Volunteers
- 53 people
- Sponsor
- Pfizer
Delayed Graft Function
Renaparin® in Kidney Transplantation
This study evaluates the safety and tolerability of Renaparin in adult patients receiving a deceased donor kidney treated ex-vivo with Renaparin prior to transplantation.
- Trial name
- NCT03773211
- Testing
- Renaparin
- Where
- 3 sites in Sweden
- Volunteers
- 16 people
- Sponsor
- Corline Biomedical AB
Delayed Graft Function, Other Complication of Kidney Transplant
I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation
The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation.
- Trial name
- NCT00802347
- Testing
- I5NP, Saline
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 374 people
- Sponsor
- Quark Pharmaceuticals
Delayed Graft Function
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
- Trial name
- ReGIFT (NCT02610296)
- Testing
- QPI-1002
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 594 people
- Sponsor
- Quark Pharmaceuticals
Graft Rejection
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
- Trial name
- NCT01147302
- Testing
- C1 Esterase Inhibitor (Human)
- Where
- 5 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- Shire
Renal Failure
Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion
The goal of this research study is to establish chimerism and avoid graft-versus-host disease in patients with kidney failure allowing a reduction or cessation of immune-suppressive therapy.
- Trial name
- NCT00498160
- Testing
- Enriched Hematopoietic Stem Cell Infusion
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Talaris Therapeutics Inc.
Kidney Transplantation
Ex Vivo Normothermic Perfusion in Kidney Transplantation.
A multicenter, prospective and open-label clinical investigation to evaluate the viability, performance and safety of ex vivo normothermic perfusion in kidney transplantation from DCD and DBD donors.
- Trial name
- KidneyARK (NCT05175885)
- Testing
- Ex vivo normothermic perfusion, Cold preservation
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Ebers Medical Technology, S.L.
The Rate of Kidney Transplants in Sensitized Patients.
Regional Kidney Paired Donor Exchange in Sensitized Patients
This is a prospective, multi-center, observational study to determine if a combination of desensitization and enrollment in a regional kidney paired donor (KPD) exchange program improves the overall rate of kidney transplantation…
- Trial name
- NCT01896089
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- BiologicTx, LLC
Renal Failure
Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)
Four subjects were treated under compassionate use provisions under this study with facilitating cell therapy (FCRx)
- Trial name
- NCT02051673
- Testing
- Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Transplant;Failure,Kidney
Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion
A significant number of deceased donor kidneys donated for transplantation are not used and are thrown away due to lack of ways of checking their condition and function before the operation.
- Trial name
- REMO-HYMAP (NCT04619732)
- Testing
- Monitoring biochemical concentrations during cold machine perfusion
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Accunea Ltd.
Kidney Transplant Rejection
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants
The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living…
- Trial name
- NCT03363945
- Testing
- MDR-101
- Where
- 19 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Medeor Therapeutics, Inc.
Delayed Graft Function
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor…
- Trial name
- NCT02474667
- Testing
- ANG-3777
- Where
- 30 sites in United States
- Volunteers
- 253 people
- Sponsor
- Angion Biomedica Corp
Kidney Transplantation
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
The purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
- Trial name
- PERSPECTIVE (NCT04803058)
- Testing
- TCD601
- Where
- 3 sites in United States, South Korea
- Volunteers
- 7 people
- Sponsor
- ITB-Med LLC
Kidney Transplantation
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor…
- Trial name
- NCT04803006
- Testing
- TCD601
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ITB-Med LLC
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Kidney Preservation and Transportation
Prospective, Single-Arm, Study to Assess the Safety and Performance of the TB1-K Device for Organ Preservation in Donor Kidneys for Transplantation
TB1-K Device is an organ preservation and transportation system, using ultrasound technology with a cooling system to preserve the organ in optimal conditions during transport to the transplant recipient.
- Trial name
- EMERGE (NCT03600285)
- Testing
- TB1-K
- Where
- 3 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Transplant Biomedicals, S.L.